Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prolonged remission in adult-onset Still's disease with etanercept.

× No keyword cloud information.

16 in total

1. Infliximab in a case of early adult-onset Still's disease.

Authors: I Olivieri; G de Stefano; A Padula; A La Gala; C de Stefano
Journal: Clin Rheumatol Date: 2003-10 Impact factor: 2.980

2. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.

Authors: B Fautrel; J Sibilia; X Mariette; B Combe
Journal: Ann Rheum Dis Date: 2004-06-07 Impact factor: 19.103

3. [Longterm outcome of TNF blockade in adult-onset Still's disease].

Authors: C Dechant; P Schauenberg; C E Antoni; H G Kraetsch; J R Kalden; B Manger
Journal: Dtsch Med Wochenschr Date: 2004-06-04 Impact factor: 0.628

Review 4. Evaluation and differential diagnosis of fibromyalgia. Approach to diagnosis and management.

Authors: P K Hench
Journal: Rheum Dis Clin North Am Date: 1989-02 Impact factor: 2.670

5. Preliminary criteria for classification of adult Still's disease.

Authors: M Yamaguchi; A Ohta; T Tsunematsu; R Kasukawa; Y Mizushima; H Kashiwagi; S Kashiwazaki; K Tanimoto; Y Matsumoto; T Ota
Journal: J Rheumatol Date: 1992-03 Impact factor: 4.666

6. Infliximab in the treatment of adult Still's disease refractory to conventional therapy.

Authors: L Cavagna; R Caporali; O Epis; F Bobbio-Pallavicini; C Montecucco
Journal: Clin Exp Rheumatol Date: 2001 May-Jun Impact factor: 4.473

7. Adult onset Still's disease in northern India: comparison with juvenile onset Still's disease.

Authors: S S Uppal; I R Pande; A Kumar; S Kailash; N G Sekharan; C M Adya; A N Malaviya
Journal: Br J Rheumatol Date: 1995-05

Review 8. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.

Authors: Roy Fleischmann; Imran Iqbal; Pallavi Nandeshwar; Andres Quiceno
Journal: Drug Saf Date: 2002 Impact factor: 5.606

9. Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients.

Authors: Alexander Kokkinos; Alexios Iliopoulos; Paraskevi Greka; Anna Efthymiou; Nicholas Katsilambros; Petros P Sfikakis
Journal: Clin Rheumatol Date: 2003-11-15 Impact factor: 2.980

Prolonged remission in adult-onset Still's disease with etanercept.

1. Infliximab in a case of early adult-onset Still's disease.

2. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases.

3. [Longterm outcome of TNF blockade in adult-onset Still's disease].

Review 4. Evaluation and differential diagnosis of fibromyalgia. Approach to diagnosis and management.

5. Preliminary criteria for classification of adult Still's disease.

6. Infliximab in the treatment of adult Still's disease refractory to conventional therapy.

7. Adult onset Still's disease in northern India: comparison with juvenile onset Still's disease.

Review 8. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.

9. Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients.

10. Adult-onset Still's disease. Clinical course and outcome.

1. Clinical features and prognosis in adult-onset Still's disease: a study of 104 cases.

Review 2. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Review 3. Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances.

4. Ten years of clinical experience with adult onset Still's disease: is the outcome improving?